Law, I. (Ian)
- Publications
- item.page.relationships.isContributorAdvisorOfPublication
- item.page.relationships.isContributorOfPublication
2 results
Search Results
Now showing 1 - 2 of 2
- EANM practice guideline/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0(2020) Herscovitch, P. (Peter); Arbizu, J. (Javier); Law, I. (Ian); Wanner, M. (Michele); Dickson, J.C. (John C.); Varrone, A. (Andrea); Douglas, D. (David); Peñuelas-Sanchez, I. (Ivan); Esposito, G. (Giuseppe); Boellaard, R. (Ronald); Drzezga, A. (Alexander); Morbelli, S. (Silvia); Garibotto, V. (Valentina); Dubroff, J. (Jacob); Ekmekcioglu, O. (Ozgul); Brooks, D.J. (David J.); Seibyl, J. (John); Tossici-Bolt, L. (Livia); Darcourt, J. (Jacques); Bohnen, N. (Nico); Semah, F. (Franck); Barthel, H. (Henryk); Kuo, P. (Phillip); Lammertsma, A. (Adriaan); Pappata, S. (Sabina); Van-Laere, K. (Koen); Zubal, G. (George); Van-de-Giessen, E. (Elsmarieke)Purpose This joint practice guideline or procedure standard was developed collaboratively by the European Association of Nuclear Medicine (EANM) and the Society of Nuclear Medicine and Molecular Imaging (SNMMI). The goal of this guideline is to assist nuclear medicine practitioners in recommending, performing, interpreting, and reporting the results of dopaminergic imaging in parkinsonian syndromes. Methods Currently nuclear medicine investigations can assess both presynaptic and postsynaptic function of dopaminergic synapses. To date both EANM and SNMMI have published procedural guidelines for dopamine transporter imaging with single photon emission computed tomography (SPECT) (in 2009 and 2011, respectively). An EANM guideline for D2 SPECT imaging is also available (2009). Since the publication of these previous guidelines, new lines of evidence have been made available on semiquantification, harmonization, comparison with normal datasets, and longitudinal analyses of dopamine transporter imaging with SPECT. Similarly, details on acquisition protocols and simplified quantification methods are now available for dopamine transporter imaging with PET, including recently developed fluorinated tracers. Finally, [18F]fluorodopa PET is now used in some centers for the differential diagnosis of parkinsonism, although procedural guidelines aiming to define standard procedures for [18F]fluorodopa imaging in this setting are still lacking. Conclusion All these emerging issues are addressed in the present procedural guidelines for dopaminergic imaging in parkinsonian syndromes.
- Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [18F]FDG: version 1.0(Springer Science and Business Media LLC, 2019) Langen, K. J (Karl-Josef); Law, I. (Ian); Albert, N. L. (Nathalie L.); Lopci, E. (Egesta); Quick, H. H. (Harald H.); Boellaard, R. (Ronald); Drzezga, A. (Alexander); Sattler, B. (Bernhard); Tonn, J. C (Jörg-Christian); Weller, M. (Michael); Galldiks, N. (Norbert); Schuster, D. M. (David M.); Fougère, C. (Christian) la; Arbizu, J. (Javier); McConathy, J. (Jonathan); Lowe, V. (Val)These joint practice guidelines, or procedure standards, were developed collaboratively by the European Association of Nuclear Medicine (EANM), the Society of Nuclear Medicine and Molecular Imaging (SNMMI), the European Association of Neurooncology (EANO), and the working group for Response Assessment in Neurooncology with PET (PET-RANO). Brain PET imaging is being increasingly used to supplement MRI in the clinical management of glioma. The aim of these standards/ guidelines is to assist nuclear medicine practitioners in recommending, performing, interpreting and reporting the results of brain PET imaging in patients with glioma to achieve a high-quality imaging standard for PET using FDG and the radiolabelled amino acids MET, FET and FDOPA. This will help promote the appropriate use of PET imaging and contribute to evidence-based medicine that may improve the diagnostic impact of this technique in neurooncological practice. The present document replaces a former version of the guidelines published in 2006 (Vander Borght et al. Eur J Nucl Med Mol Imaging. 33:1374–80, 2006), andsupplements a recent evidence-based recommendation by the PET-RANO working group and EANO on the clinical use of PET imaging in patients with glioma (Albert et al. Neuro Oncol. 18:1199–208, 2016). The information provided should be taken in the context of local conditions and regulations.